Four weight loss researchers discussed the value of behavioral therapy, intensive lifestyle interventions, and pharmacotherapy during a Scientific Sessions symposium on Sunday, June 5. “There’s quite a bit of evidence showing that individuals who self-monitor over time generally are the best in terms of maintenance of behaviors and weight,” said Hollie Raynor, PhD, RD, LDN.

Carol H. Wysham, MD, says there is serious therapeutic inertia at play as patients often remain in poor glycemic control for more than seven years before intensification of treatment. Yet repeated studies show that up-titrating GLP-1 receptor agonist dosing improves glycemic outcomes as well as loss and maintenance of weight.

An expert panel including Paul McGuigan, RN, CDCES, stressed that creating a continuum of care and support starting in high school, including promoting health insurance literacy, is key to setting up young people with type 2 diabetes to successfully manage their disease as they transition to adulthood.

Most type 2 diabetes complications are related to excess adiposity, Dina Griauzde, MD, MSc, explained at the 82nd Scientific Sessions. Experts explored the benefits of weight loss for patients with type 2 diabetes, as well as medical management and surgical options for achieving weight loss.

Last year, an international group of experts convened by the ADA published a consensus report on the clinical definition of “remission” in type 2 diabetes. During the 82nd Scientific Sessions, members of the consensus report writing group, including Philip Schauer, MD, discussed the rationale behind the report’s recommendations.

Phase 2 trial results suggest retatrutide may offer a triple therapy option to address the multiple metabolic factors that affect people who are obese, regardless of type 2 diabetes status, said Arun J. Sanyal, MD. He and other investigators will share new data on this GIP/GLP-1/glucagon receptor triagonist and its effects on obesity, type 2…

Carmella Evans-Molina, MD, PhD, this year’s Outstanding Scientific Achievement Award winner, was first interested in understanding the beta-cell pathways that drive the transition from normoglycemia to dysglycemia to diabetes. Now she is focusing on ways to leverage beta-cell stress to inform type 1 diabetes biomarker development.

A1C has long been the gold standard for assessing glycemic control in diabetes over time, but continuous glucose monitoring (CGM) metrics such as time in range (TIR) are increasingly becoming popular because they represent real-time results. Revital Nimri, MD, and other experts discussed the role of TIR and other CGM metrics that use the most…

A panel of experts analyzed the effects of physical activity on older adults with diabetes to determine potential therapeutic interventions. Bruce A. Perkins, MD, MPH, discussed his research into longevity in type 1 diabetes and the benefits physical activity has on beta-cell reserve.